Analysts Set NewLink Genetics Corp (NLNK) PT at $25.67

NewLink Genetics Corp (NASDAQ:NLNK) has received an average recommendation of “Buy” from the nine brokerages that are covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $25.67.

A number of equities analysts have recently issued reports on the company. ValuEngine downgraded NewLink Genetics from a “sell” rating to a “strong sell” rating in a research note on Tuesday, September 26th. Zacks Investment Research downgraded NewLink Genetics from a “buy” rating to a “hold” rating in a research note on Thursday, January 4th. BidaskClub upgraded NewLink Genetics from a “sell” rating to a “hold” rating in a research report on Friday, January 5th. Cantor Fitzgerald reiterated a “buy” rating and set a $26.00 target price on shares of NewLink Genetics in a research report on Monday, September 25th. Finally, Stifel Nicolaus lifted their target price on NewLink Genetics from $25.00 to $29.00 and gave the company a “buy” rating in a research report on Friday, November 3rd.

NewLink Genetics (NASDAQ NLNK) traded up $0.18 during mid-day trading on Tuesday, hitting $8.62. The stock had a trading volume of 471,612 shares, compared to its average volume of 955,777. The stock has a market cap of $312.23, a P/E ratio of -3.53 and a beta of 1.10. NewLink Genetics has a 52-week low of $5.90 and a 52-week high of $25.17.

NewLink Genetics (NASDAQ:NLNK) last released its quarterly earnings results on Thursday, November 2nd. The biotechnology company reported ($0.69) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.74) by $0.05. NewLink Genetics had a negative return on equity of 63.39% and a negative net margin of 229.19%. research analysts forecast that NewLink Genetics will post -2.65 earnings per share for the current year.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in NLNK. Perceptive Advisors LLC purchased a new position in NewLink Genetics during the third quarter valued at $4,581,000. Candriam Luxembourg S.C.A. lifted its position in NewLink Genetics by 337.3% during the third quarter. Candriam Luxembourg S.C.A. now owns 328,000 shares of the biotechnology company’s stock valued at $3,339,000 after purchasing an additional 253,000 shares in the last quarter. Ameriprise Financial Inc. lifted its position in NewLink Genetics by 207.1% during the third quarter. Ameriprise Financial Inc. now owns 311,927 shares of the biotechnology company’s stock valued at $3,176,000 after purchasing an additional 210,360 shares in the last quarter. Point72 Asset Management L.P. purchased a new position in NewLink Genetics during the third quarter valued at $1,819,000. Finally, GSA Capital Partners LLP lifted its position in NewLink Genetics by 653.7% during the third quarter. GSA Capital Partners LLP now owns 132,154 shares of the biotechnology company’s stock valued at $1,345,000 after purchasing an additional 114,620 shares in the last quarter. Institutional investors own 52.63% of the company’s stock.

WARNING: This story was first published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this story on another website, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The original version of this story can be accessed at https://ledgergazette.com/2018/02/11/analysts-set-newlink-genetics-corp-nlnk-pt-at-25-67.html.

About NewLink Genetics

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.

Analyst Recommendations for NewLink Genetics (NASDAQ:NLNK)

Receive News & Ratings for NewLink Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply